Grant: Idea to Innovation
University of Toronto
$122,372.00
Mobile heath app screening for male fertility
EF 2017-18
Résumé
DigiSperm is a rapid, point-of-care, low-cost device that uses paper-based microfluidic technology to quantify male fertility potential. The device simultaneously measures three critical semen parameters for male fertility diagnosis in 10 min: live sperm concentration, motile sperm concentration, and motility. In preliminary side-by-side clinical testing, DigiSperm provided identical outcomes to the current clinical gold-standard, computer-assisted semen analysis (CASA) - an expensive lab technique to which few have access. In contrast, DigiSperm provides direct visual readout with straightforward and quantitative analysis of semen parameters, allowing direct imaging with a smartphone app for instantaneous analysis, readout, tracking and communication of the health result. Our medical collaborators refer to this technology as a 'fitbit for sperm', referring to the popular mobile health monitoring app. Technical improvements and proof-of-concept validation testing are required, however, to adapt this device for widespread commercial mobile health diagnosis. The targeted research and proof-of-concept testing proposed here are essential to engaging investors, in keeping with the I2I Phase I program.The proposed project has three specific objectives: i) develop a robust user-friendly fluid delivery interface; ii) optimize the device for smartphone/mobile health diagnosis; iii) perform necessary clinical validation and testing essential to engage early-stage investment.The project benefits from a strong network of support and collaborations including Dr. Keith Jarvi (Head of Urology at Mount Sinai Hospital), the Hannam Fertility Centre, MaRS Innovation, the Kangaroo Group (Productization consultants), and the makers of ClearBlue (the worldwide standard in female fertility tests), in addition to cash support for addition patenting costs from the U of T.
Programme
Idea to Innovation
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
505850-2017
Name nom
Sinton, David
Department département
Mechanical and Industrial Engineering
Organization id
31
Institution établissement
University of Toronto
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2017
Competition year année de concours
2017
Award amount
122372
Program id
I2IPJ
Program name en
Idea to Innovation
Program name fr
De l'idée à l'innovation
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
518
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Medical equipment and apparatus
Area of application fr
Appareils et instruments médicaux
Research subject code
1901
Research subject group en
Biomedical engineering
Research subject group fr
Génie biomédical
Research subject en
Biomedical technology
Research subject fr
Technologie biomédicale
Partie
1
Nb partie
1
Application title
Mobile heath app screening for male fertility
Keyword
NSERC
Application summary
DigiSperm is a rapid, point-of-care, low-cost device that uses paper-based microfluidic technology to quantify male fertility potential. The device simultaneously measures three critical semen parameters for male fertility diagnosis in 10 min: live sperm concentration, motile sperm concentration, and motility. In preliminary side-by-side clinical testing, DigiSperm provided identical outcomes to the current clinical gold-standard, computer-assisted semen analysis (CASA) - an expensive lab technique to which few have access. In contrast, DigiSperm provides direct visual readout with straightforward and quantitative analysis of semen parameters, allowing direct imaging with a smartphone app for instantaneous analysis, readout, tracking and communication of the health result. Our medical collaborators refer to this technology as a 'fitbit for sperm', referring to the popular mobile health monitoring app. Technical improvements and proof-of-concept validation testing are required, however, to adapt this device for widespread commercial mobile health diagnosis. The targeted research and proof-of-concept testing proposed here are essential to engaging investors, in keeping with the I2I Phase I program.The proposed project has three specific objectives: i) develop a robust user-friendly fluid delivery interface; ii) optimize the device for smartphone/mobile health diagnosis; iii) perform necessary clinical validation and testing essential to engage early-stage investment.The project benefits from a strong network of support and collaborations including Dr. Keith Jarvi (Head of Urology at Mount Sinai Hospital), the Hannam Fertility Centre, MaRS Innovation, the Kangaroo Group (Productization consultants), and the makers of ClearBlue (the worldwide standard in female fertility tests), in addition to cash support for addition patenting costs from the U of T.